Alcohol Use Disorder: Symptoms, Causes & Treatment

Alcohol use disorder (AUD) is a chronic, relapsing brain disease affecting approximately 283 million people globally. It is defined by compulsive alcohol seeking and use despite harmful consequences, impaired control over intake, and the emergence of a negative emotional state when alcohol is unavailable. Modern neuroscience frames AUD as a neurobiological disorder — not a moral failing — involving dysregulation of the brain's reward (dopamine/opioid), stress (CRF/dynorphin), and executive control (prefrontal cortex) circuits. Chronic alcohol exposure dysregulates GABA and glutamate neurotransmitter systems, blunting natural reward responses while amplifying craving.

AUD exists on a severity spectrum from mild to severe, classified by the number of DSM-5 diagnostic criteria met. Key features include: inability to cut down despite desire, craving, tolerance (needing more for the same effect), withdrawal symptoms on cessation (tremor, sweating, anxiety, seizures), and continued use despite social, occupational, or health consequences. Alcohol is causally linked to at least seven cancer types (liver, esophagus, colorectal, breast, etc.) and is a leading contributor to preventable mortality worldwide.

Effective evidence-based treatments exist: pharmacotherapy with naltrexone (reduces craving), acamprosate (reduces protracted withdrawal symptoms), and disulfiram (aversion therapy), combined with behavioral interventions including cognitive-behavioral therapy (CBT), motivational enhancement therapy, and peer support groups (Alcoholics Anonymous). Medically supervised detoxification is required for moderate-to-severe withdrawal. Recovery is achievable — relapse is part of the disease course, not a sign of failure.

• Inability to control or stop alcohol intake despite repeated attempts
• Intense craving and preoccupation with drinking
• Withdrawal symptoms on cessation: tremor, diaphoresis, anxiety, nausea, seizures, delirium tremens
• Tolerance: requiring increasing amounts for the same effect
• Neglecting responsibilities, relationships, and previously enjoyed activities
• Continued use despite clear physical, psychological, or social harm

• Genetic predisposition accounts for 40–60% of AUD risk; multiple susceptibility genes identified
• Neurobiological dysregulation: altered GABA, glutamate, dopamine, and endogenous opioid systems
• Environmental factors: early onset drinking, peer influence, childhood adversity, trauma
• Psychiatric comorbidities: anxiety disorders, depression, PTSD (self-medication hypothesis)
• Social and cultural factors: availability, social drinking norms, occupational stress

Diagnosis uses DSM-5 criteria (11 symptoms; mild=2–3, moderate=4–5, severe=6+). Validated screening tools include the AUDIT (Alcohol Use Disorders Identification Test) and CAGE questionnaire. Laboratory markers supporting diagnosis: elevated GGT, carbohydrate-deficient transferrin (CDT), macrocytosis (MCV >100 fL), elevated liver transaminases (AST:ALT ratio >2 suggests alcoholic hepatitis). Comorbid mental health conditions should be assessed.

Management begins with medically supervised alcohol detoxification using benzodiazepines (diazepam or chlordiazepoxide via CIWA-Ar protocol) to prevent seizures and delirium tremens. Pharmacotherapy: naltrexone (opioid antagonist, reduces craving and relapse rate), acamprosate (modulates glutamate, reduces protracted withdrawal), disulfiram (acetaldehyde accumulation aversion). Behavioral treatment: CBT, motivational enhancement therapy, 12-step facilitation, and family therapy. Residential or intensive outpatient programs for moderate-to-severe cases. Dual diagnosis treatment for psychiatric comorbidities is essential.

• Liver disease spectrum: alcoholic fatty liver → alcoholic hepatitis → cirrhosis → hepatocellular carcinoma
• Pancreatitis: acute and chronic; exocrine and endocrine insufficiency
• Cardiovascular: alcoholic cardiomyopathy, atrial fibrillation (holiday heart), hypertension
• Neurological: peripheral neuropathy, cerebellar atrophy, Wernicke-Korsakoff syndrome (thiamine deficiency)
• Cancers: liver, esophagus, oropharynx, breast, colorectal
• Trauma, accidents, social and occupational deterioration

• Public education on alcohol risks and safe drinking limits
• Brief intervention by primary care providers using validated screening (AUDIT-C, CAGE)
• Early psychological support for high-risk individuals (family history, trauma, depression)
• Public health policies: taxation, advertising restrictions, minimum drinking age, treatment accessibility